Targets › BCHE
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Nov 2028.
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. (UniProt, P06276)
Open in Phaseline: the race on BCHE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Washington University School of Medicine | Rivastigmine Cholinesterases; ACHE & BCHE inhibitor | BCHE, ACHE | Phase 2 | Anticholinergic Toxicity | Nov 2028 |
Anticholinergic Toxicity (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.